BioTime Initiates Dosing in Phase I/IIa Clinical Study of OpRegen for Treatment of Dry-AMD Utilizing Orbit Subretinal Delivery System – Maryville Daily Times

BioTime Initiates Dosing in Phase I/IIa Clinical Study of OpRegen for Treatment of Dry-AMD Utilizing Orbit Subretinal Delivery System Maryville Daily Times

ALAMEDA, Calif.–(BUSINESS WIRE)–Jul 11, 2019–. BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing …

…read more

Source:: Alameda, California News By Google News

[ghozylab-instagram feed=26796]